| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgery, University Hospital Basel, Basel, Switzerland
2 Bethanien Clinic, Zurich, Switzerland
3 Division of Gynecology, University Hospital Berne, Berne, Switzerland
4 Institute of Pathology, University Hospital Basel, Basel, Switzerland
5 Department of Obstetrics and Gynecology, Kantonsspital Aarau, Aarau, Switzerland
6 Division of Gynecology, University Hospital Zurich, Zurich, Switzerland
7 Division of Gynecology, Kantonsspital Winterthur, Winterthur, Switzerland
8 Department of Obstetrics and Gynecology, Ospedale San Giovanni, Bellinzona, Switzerland
9 Maternité, Stadtspital Triemli, Zurich, Switzerland
10 Division of Gynecology, University Hospital Basel, Basel, Switzerland
11 Department of Obstetrics and Gynecology, Kantonsspital Bruderholz, Binningen, Switzerland
12 Department of Obstetrics and Gynecology, Kantonales Spital Sursee-Wolhusen, Sursee, Wolhusen, Switzerland
13 Department of Surgery, Kantonsspital Olten, Olten, Switzerland
Correspondence: Address correspondence and reprint requests to: Markus Zuber, MD; E-mail: mzuber_ol{at}spital.ktso.ch
Background: The sentinel lymph node (SLN) status has proven to accurately reflect the remaining axillary lymph nodes and represents the most important prognostic factor. It is unknown whether an association exists between the SLN status and the presence of bone marrow (BM) micrometastases. The objective of the present investigation was to evaluate whether or not such an association exists.
Methods: In the present investigation 410 patients with early stage breast cancer (pT1 and pT2
3cm, cN0) were prospectively enrolled between 1/2000 and 12/2003. All patients underwent SLN biopsy and bone marrow aspiration. The histological examination of the SLN consisted of step sectioning, H&E, and immunohistochemistry (Lu-5, CK 22) staining. Cancer cells in the BM were stained with monoclonal antibodies A45-B/B3 against cytokeratin and counted by an automated computerized digital microscope.
Results: BM micrometastases were detected in 28.8% (118/410) of all patients. The SLN contained metastases in 32.4% (133/410). Overall 51.2% of the patients (210/410) were SLN negative/BM negative and 12.4% (51/410) SLN positive/BM positive. Of all patients, 16.4% (67/410) were SLN negative/BM positive and 20.0% (82/410) SLN positive/BM negative. There was a statistically significant association between the SLN and BM status, both in unadjusted (Fishers exact test: P = .004) and multiple logistic regression analysis (P = .007).
Conclusions: In the present investigation a significant association was found between a positive SLN status and the presence of BM micrometastases. Nonetheless, the percentage of non-concordance (SLN negative/BM positive and SLN positive/BM negative) was considerable. The prognostic impact of BM micrometastases in our patient sample remains to be evaluated.
Key Words: Breast cancer Sentinel lymph node Bone marrow micrometastases Correlation Multicenter trial
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |